Literature DB >> 32338096

Isolated trisomy 11 in patients with acute myeloid leukemia - is the prognosis not as grim as previously thought?

Jan Philipp Bewersdorf1, Rory M Shallis1, Autumn Diadamo2, Lohith Gowda1, Nikolai A Podoltsev1, Alexa Siddon3,4, Amer M Zeidan1,5.   

Abstract

Entities:  

Keywords:  AML; Acute myeloid leukemia; genetics; outcome; trisomy 11

Mesh：

Substances：

Year:  2020        PMID： 32338096      PMCID： PMC7485109          DOI： 10.1080/10428194.2020.1755858

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  14 in total

1.  Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry.

Authors:  Vladimir Lj Lazarevic; Aldana Rosso; Gunnar Juliusson; Petar Antunovic; Åsa Rangert Derolf; Stefan Deneberg; Lars Möllgård; Bertil Uggla; Lovisa Wennström; Anders Wahlin; Martin Höglund; Sören Lehmann; Bertil Johansson
Journal:  Eur J Haematol       Date:  2017-03-09       Impact factor: 2.997

2.  Genomic Classification and Prognosis in Acute Myeloid Leukemia.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Hartmut Döhner; Peter J Campbell; Lars Bullinger; Verena I Gaidzik; Peter Paschka; Nicola D Roberts; Nicola E Potter; Michael Heuser; Felicitas Thol; Niccolo Bolli; Gunes Gundem; Peter Van Loo; Inigo Martincorena; Peter Ganly; Laura Mudie; Stuart McLaren; Sarah O'Meara; Keiran Raine; David R Jones; Jon W Teague; Adam P Butler; Mel F Greaves; Arnold Ganser; Konstanze Döhner; Richard F Schlenk
Journal:  N Engl J Med       Date:  2016-06-09       Impact factor: 91.245

3.  Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21.

Authors:  Bhavana Bhatnagar; Ann-Kathrin Eisfeld; Jessica Kohlschmidt; Krzysztof Mrózek; Deedra Nicolet; Dimitrios Papaioannou; Christopher J Walker; Shelley Orwick; James S Blachly; Jonathan E Kolitz; Bayard L Powell; Andrew J Carroll; Richard M Stone; John C Byrd; Clara D Bloomfield
Journal:  Leukemia       Date:  2019-08-28       Impact factor: 11.528

4.  Adult chronic myelomonocytic leukemia with trisomy 11: a case report.

Authors:  S H Yoo; J Lim; J M Byun; J H Park; K H Kim; I S Choi
Journal:  Curr Oncol       Date:  2017-12-20       Impact factor: 3.677

5.  Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis.

Authors:  Tobias Herold; Klaus H Metzeler; Sebastian Vosberg; Luise Hartmann; Christoph Röllig; Friedrich Stölzel; Stephanie Schneider; Max Hubmann; Evelyn Zellmeier; Bianka Ksienzyk; Vindi Jurinovic; Zlatana Pasalic; Purvi M Kakadia; Annika Dufour; Alexander Graf; Stefan Krebs; Helmut Blum; Maria Cristina Sauerland; Thomas Büchner; Wolfgang E Berdel; Bernhard J Woermann; Martin Bornhäuser; Gerhard Ehninger; Ulrich Mansmann; Wolfgang Hiddemann; Stefan K Bohlander; Karsten Spiekermann; Philipp A Greif
Journal:  Blood       Date:  2014-06-12       Impact factor: 22.113

6.  Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?

Authors:  Jan Philipp Bewersdorf; Maximilian Stahl; Amer M Zeidan
Journal:  Leuk Lymphoma       Date:  2019-01-17

Review 7.  Trisomy 11 in chronic myelomonocytic leukemia: report of two cases and review of the literature.

Authors:  N Takasaki; Y Kaneko; N Maseki; M Sakurai
Journal:  Cancer Genet Cytogenet       Date:  1988-01

8.  Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features.

Authors:  S A Wang; K Jabbar; G Lu; S S Chen; N Galili; F Vega; D Jones; A Raza; H Kantarjian; G Garcia-Manero; T J McDonnell; L J Medeiros
Journal:  Leukemia       Date:  2010-01-14       Impact factor: 11.528

9.  Trisomy 11: an association with stem/progenitor cell immunophenotype.

Authors:  M L Slovak; S T Traweek; C L Willman; D R Head; K J Kopecky; R E Magenis; F R Appelbaum; S J Forman
Journal:  Br J Haematol       Date:  1995-06       Impact factor: 6.998

10.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Authors:  Courtney D DiNardo; Keith Pratz; Vinod Pullarkat; Brian A Jonas; Martha Arellano; Pamela S Becker; Olga Frankfurt; Marina Konopleva; Andrew H Wei; Hagop M Kantarjian; Tu Xu; Wan-Jen Hong; Brenda Chyla; Jalaja Potluri; Daniel A Pollyea; Anthony Letai
Journal:  Blood       Date:  2018-10-25       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.